Background
Clostridioides difficile infection (CDI) immune response is influenced by the innate and adaptive (humoral) immune systems. Our prior research found attenuated humoral responses to C. difficile in immunocompromised hosts (ICHs) with CDI. We sought to evaluate whether the innate immune response to CDI was influenced by ICH status.
Methods
We conducted a prospective study of hospitalized adults with CDI (acute diarrhea, positive C. difficile stool nucleic acid amplification testing (NAAT), and decision to treat), with and without immunosuppression and measured a panel of cytokines (G-CSF, IL-10, IL-15, IL-1β, IL-4, IL-6, IL-8, and TNF-α) in blood and stool at CDI diagnosis. Results were compared with measurements from a cohort of asymptomatic carrier patients (ASC) (NAAT positive, without diarrhea) with and without immunocompromise.
Results
123 subjects (42 ICHs, 50 non-ICHs, 31 ASCs) were included. Median values for blood and stool cytokines were similar in ICH versus non-ICH CDI subjects. In blood, G-CSF, IL-10, IL-15, IL-6 and IL-8 were higher in both groups of CDI subjects versus the ASC cohort (P <0.05). In stool, IL-1β and IL-8 were higher in both groups of CDI subjects versus the ASC cohort (P <0.05). Stool concentrations of IL-1β demonstrated significant differences between the groups (median: ICHs 10.97 pg/mL, non-ICH: 9.71 pg/mL and ASC 0.56 pg/mL) (P<0.0001).
Conclusions
In this small exploratory analysis, ICH status did not significantly impact blood and fecal patterns of cytokines in humans at the diagnosis of CDI, suggesting that the innate immune response to C. difficile may be conserved in immunocompromised patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.